MHRA
- Local brand name: Bortezomib Hospira
- Status: approved
🇬🇧 Velcade in United Kingdom
NICE has issued 13 UK HTA decisions
Marketing authorisation
Health technology assessment
13 decisions from NICE for Velcade in United Kingdom.
NICE TA897 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Velcade for the treatment of previously treated multiple myeloma. This decision was made based on a commercial arrangement, which suggests that a patient access scheme was in place to make the treatment more affordable. No restrictions were placed on the use of Velcade.
NICE TA311 — ✓ Recommended
- Indication assessed: induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE recommended Velcade for the treatment of multiple myeloma. This decision was made for the indication of induction therapy before high-dose chemotherapy and autologous stem cell transplantation. No cost basis was reported, and no restriction or condition was applied.
NICE TA228 — ✓ Recommended
- Indication assessed: the first‑line treatment of multiple myeloma
NICE recommended Velcade for the first-line treatment of multiple myeloma. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Velcade.
NICE TA129 — ✓ Recommended
- Indication assessed: relapsed multiple myeloma
NICE recommended Velcade for the treatment of relapsed multiple myeloma. This decision was made without a reported cost-effectiveness analysis or a Patient Access Scheme. No commercial arrangement or restriction was applied to the recommendation.
NICE TA427 — ✓ Recommended
- Indication assessed: multiple myeloma previously treated with lenalidomide and bortezomib
NICE recommended Velcade for the treatment of multiple myeloma in patients who have previously received lenalidomide and bortezomib. This decision was made based on a commercial arrangement and a patient access scheme. No restrictions were placed on the use of Velcade.
NICE TA974 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Velcade for the treatment of previously treated multiple myeloma. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Velcade.
NICE TA771 — — Appraisal terminated
- Indication assessed: untreated multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Velcade for the treatment of untreated multiple myeloma. This decision means that the appraisal process for Velcade in this indication has been stopped. The decision was made without a recommendation on the cost-effectiveness of Velcade, as the appraisal was terminated.
NICE TA603 — — Appraisal terminated
- Indication assessed: untreated multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Velcade for the treatment of untreated multiple myeloma. This decision means that the appraisal process for Velcade in this indication has been stopped. The decision was made without a recommendation on the cost-effectiveness of Velcade, as the appraisal was terminated.
NICE TA1149 — — Decision pending classification
- Indication assessed: previously treated multiple myeloma
NICE recommended Velcade for the treatment of previously treated multiple myeloma. The decision was made based on a commercial arrangement. No restriction or condition was placed on the use of Velcade.
NICE TA602 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Velcade for treating relapsed or refractory multiple myeloma. This decision means that the appraisal process for Velcade in this indication has been stopped. The decision was made without a recommendation on the cost-effectiveness of Velcade, as the appraisal was terminated.
NICE TA586 — ✓ Recommended
- Indication assessed: multiple myeloma after 1 treatment with bortezomib
NICE recommended Velcade for the treatment of multiple myeloma in patients who have previously received bortezomib. This decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or terms for the drug. There were no restrictions or conditions placed on the use of Velcade for this indication.
NICE TA453 — — Appraisal terminated
- Indication assessed: treating multiple myeloma after second or subsequent relapse (terminated appraisal)
NICE made a decision to terminate the appraisal of Velcade for treating multiple myeloma after second or subsequent relapse. This decision was made without a recommendation on the cost-effectiveness of the treatment. The appraisal was terminated, which means that NICE did not make a recommendation on the use of Velcade for this indication.
NICE TA370 — ✓ Recommended
- Indication assessed: previously untreated mantle cell lymphoma
NICE recommended Velcade for the treatment of previously untreated mantle cell lymphoma. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Velcade for this indication.
Velcade in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Velcade approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Velcade in United Kingdom?
Shilpa is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Velcade been assessed by UK health technology agencies?
Yes — 13 UK HTA decisions on record from NICE.